Health
This is to provide Latest HealthNews around the globe
-
Misconceptions keep some cancer patient populations from benefiting from hormone therapy, survey reveals
Credit: Pixabay/CC0 Public Domain Despite evidence suggesting the safety of hormone therapy for patients with a history of low-grade endometrial or epithelial ovarian cancer, a new survey shows that many gynecologists and some gynecologic oncologists are still uncomfortable prescribing the therapy for this patient population. This indicates a need for more clinician education to help overcome lingering misconceptions. Survey results…
Read More » -
Speeding up cardiac emergency response
In an evolving health landscape, emerging research continues to highlight concerns that could impact everyday wellbeing. Here’s the key update you should know about: A UK trial shows drones can deliver defibrillators faster than ambulances, but survival depends on better dispatcher guidance and bystander confidence in using the life-saving devices. Study: The use of drone-delivered Automated External Defibrillators in the emergency…
Read More » -
Ketamine therapy, teenage depression and what’s really going on
Does ketamine therapy offer a way out of depression? Ketamine therapy is an emerging treatment for severe, treatment-resistant depression and related mental health conditions. unbranded – Lifestyle Jacintha was at her wits’ end. Her daughter was struggling, and they had tried everything ‒ two types of antidepressants, years of talk therapy and weeks of an intensive outpatient program. She was…
Read More » -
Humana (HUM) Teams Up with Vori Health and HOPCo to Enhance Patient Outcomes
Humana Inc. (NYSE:HUM) ranks among the best performing S&P 500 stocks in the last 3 months. In a bid to improve care for Medicare Advantage members with musculoskeletal conditions, Humana Inc. (NYSE:HUM) announced new value-based care agreements with Vori Health and HOPCo on August 27. Valeri Potapova/Shutterstock.com Through these collaborations, qualified Humana Medicare Advantage members will have access to care…
Read More » -
Researchers Criticize Putting Preschoolers on Stimulant Drugs
In a new study, researchers found that preschoolers are not receiving appropriate guideline-directed care for ADHD. Clinical practice guidelines for this age group recommend beginning with family/behavioral therapy. Drugs are recommended by the guidelines only after therapy has failed to improve the situation or in very severe cases. But the researchers found that 42.2% of…
Read More » -
Keto diet linked to reduced depression symptoms in college students
Credit: CC0 Public Domain A new study shows an association between at least 10 weeks of following a well-formulated ketogenic diet and a roughly 70% decrease in depression symptoms among a small group of college students. Beyond the reduction in self-reported and clinician-rated depression, the students’ global well-being increased nearly three-fold and their performance improved on several cognitive tasks. All…
Read More » -
Simple support tools improve blood pressure management in hypertensive patients
In an evolving health landscape, emerging research continues to highlight concerns that could impact everyday wellbeing. Here’s the key update you should know about: For some patients struggling to control high blood pressure, something as simple as having blood pressure monitors at home and texted reminders to use them could be the key to stabilizing or even lowering their blood…
Read More » -
FDA Approves Risperidone Extended-Release Injectable Suspension
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals risperidone extended-release (ER) injectable suspension, an atypical antipsychotic for treatment of schizophrenia and maintenance of bipolar 1 disorder.1 The approval was based on phase 3 trial results, which included a double-blind placebo-controlled trial, along with a 52-week open-label study of the medication. Over the 12 months of exposure in…
Read More » -
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space, with Madrigal’s Rezdiffra becoming the first approved drug in the EU for patients with MASH and moderate-to-advanced fibrosis (F2–3). Shortly after, Novo Nordisk’s Wegovy was approved in the US for MASH F2–3, providing the first direct competition to Rezdiffra, which until now…
Read More » -
Warming climate drives dengue surge across Asia and the Americas, study shows
Predicted increases in dengue fever incidence by 2050. Credit: Proceedings of the National Academy of Sciences (2025). DOI: 10.1073/pnas.2512350122 Warmer weather across the globe is reshaping the landscape of human health. A case in point is dengue fever, a mosquito-borne disease once confined largely to the tropics, which often brings flu-like symptoms, and without proper medical care, can escalate to…
Read More »
